vs
Side-by-side financial comparison of Arcellx, Inc. (ACLX) and Cellectis S.A. (CLLS). Click either name above to swap in a different company.
Cellectis S.A. is the larger business by last-quarter revenue ($9.5M vs $8.1M, roughly 1.2× Arcellx, Inc.). Cellectis S.A. runs the higher net margin — -265.9% vs -766.0%, a 500.1% gap on every dollar of revenue. On growth, Cellectis S.A. posted the faster year-over-year revenue change (375.0% vs -79.3%). Cellectis S.A. produced more free cash flow last quarter ($27.6M vs $-63.9M).
Arcellx, Inc. is a clinical-stage biotechnology company that develops innovative chimeric antigen receptor T (CAR-T) cell therapies for treating hard-to-treat cancers including hematologic malignancies and solid tumors. Its core pipeline targets unmet oncology medical needs, serving global patient populations and partnering with life sciences stakeholders.
Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina.
ACLX vs CLLS — Head-to-Head
Income Statement — Q1 FY2025 vs Q2 FY2024
| Metric | | |
|---|---|---|
| Revenue | $8.1M | $9.5M |
| Net Profit | $-62.3M | $-25.3M |
| Gross Margin | — | — |
| Operating Margin | -847.6% | -181.1% |
| Net Margin | -766.0% | -265.9% |
| Revenue YoY | -79.3% | 375.0% |
| Net Profit YoY | -765.1% | -51.9% |
| EPS (diluted) | $-1.13 | $-0.28 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 25 | $8.1M | — | ||
| Q4 24 | $15.3M | — | ||
| Q3 24 | $26.0M | — | ||
| Q2 24 | $27.4M | $9.5M | ||
| Q1 24 | $39.3M | — | ||
| Q4 23 | $63.1M | — | ||
| Q3 23 | $15.0M | $1.6M | ||
| Q2 23 | $14.3M | $2.0M |
| Q1 25 | $-62.3M | — | ||
| Q4 24 | $-47.1M | — | ||
| Q3 24 | $-25.9M | — | ||
| Q2 24 | $-27.2M | $-25.3M | ||
| Q1 24 | $-7.2M | — | ||
| Q4 23 | $19.8M | — | ||
| Q3 23 | $-39.3M | $-17.5M | ||
| Q2 23 | $-23.9M | $-16.6M |
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | 97.3% |
| Q1 25 | -847.6% | — | ||
| Q4 24 | -348.2% | — | ||
| Q3 24 | -129.1% | — | ||
| Q2 24 | -127.8% | -181.1% | ||
| Q1 24 | -40.3% | — | ||
| Q4 23 | 23.8% | — | ||
| Q3 23 | -299.9% | -1258.1% | ||
| Q2 23 | -206.7% | -1180.5% |
| Q1 25 | -766.0% | — | ||
| Q4 24 | -308.4% | — | ||
| Q3 24 | -99.4% | — | ||
| Q2 24 | -99.3% | -265.9% | ||
| Q1 24 | -18.3% | — | ||
| Q4 23 | 31.4% | — | ||
| Q3 23 | -263.0% | -1064.1% | ||
| Q2 23 | -166.8% | -831.6% |
| Q1 25 | $-1.13 | — | ||
| Q4 24 | $-0.87 | — | ||
| Q3 24 | $-0.48 | — | ||
| Q2 24 | $-0.51 | $-0.28 | ||
| Q1 24 | $-0.14 | — | ||
| Q4 23 | $0.42 | — | ||
| Q3 23 | $-0.81 | $-0.31 | ||
| Q2 23 | $-0.50 | $-0.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $543.3M | $149.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $416.9M | $148.6M |
| Total Assets | $648.1M | $407.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 25 | $543.3M | — | ||
| Q4 24 | $587.4M | — | ||
| Q3 24 | $574.3M | — | ||
| Q2 24 | $516.7M | $149.0M | ||
| Q1 24 | $573.9M | — | ||
| Q4 23 | $702.0M | — | ||
| Q3 23 | $439.7M | — | ||
| Q2 23 | $506.5M | $84.4M |
| Q1 25 | $416.9M | — | ||
| Q4 24 | $454.8M | — | ||
| Q3 24 | $483.0M | — | ||
| Q2 24 | $487.2M | $148.6M | ||
| Q1 24 | $496.6M | — | ||
| Q4 23 | $485.4M | — | ||
| Q3 23 | $266.1M | $76.1M | ||
| Q2 23 | $293.7M | $96.6M |
| Q1 25 | $648.1M | — | ||
| Q4 24 | $711.3M | — | ||
| Q3 24 | $764.9M | — | ||
| Q2 24 | $734.3M | $407.1M | ||
| Q1 24 | $779.7M | — | ||
| Q4 23 | $825.1M | — | ||
| Q3 23 | $614.2M | $209.7M | ||
| Q2 23 | $623.5M | $227.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-63.1M | $28.9M |
| Free Cash FlowOCF − Capex | $-63.9M | $27.6M |
| FCF MarginFCF / Revenue | -786.4% | 290.5% |
| Capex IntensityCapex / Revenue | 9.6% | 13.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-122.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 25 | $-63.1M | — | ||
| Q4 24 | $-46.0M | — | ||
| Q3 24 | $30.7M | — | ||
| Q2 24 | $-36.2M | $28.9M | ||
| Q1 24 | $-31.9M | — | ||
| Q4 23 | $58.2M | — | ||
| Q3 23 | $-10.1M | — | ||
| Q2 23 | $-22.6M | $-47.4M |
| Q1 25 | $-63.9M | — | ||
| Q4 24 | $-47.5M | — | ||
| Q3 24 | $28.4M | — | ||
| Q2 24 | $-39.5M | $27.6M | ||
| Q1 24 | $-38.3M | — | ||
| Q4 23 | $53.0M | — | ||
| Q3 23 | $-18.0M | — | ||
| Q2 23 | $-29.8M | $-47.9M |
| Q1 25 | -786.4% | — | ||
| Q4 24 | -311.3% | — | ||
| Q3 24 | 109.2% | — | ||
| Q2 24 | -144.1% | 290.5% | ||
| Q1 24 | -97.7% | — | ||
| Q4 23 | 83.9% | — | ||
| Q3 23 | -120.5% | — | ||
| Q2 23 | -208.7% | -2391.4% |
| Q1 25 | 9.6% | — | ||
| Q4 24 | 9.8% | — | ||
| Q3 24 | 8.8% | — | ||
| Q2 24 | 11.7% | 13.2% | ||
| Q1 24 | 16.4% | — | ||
| Q4 23 | 8.4% | — | ||
| Q3 23 | 53.0% | — | ||
| Q2 23 | 50.5% | 24.1% |
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | 2.94× | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
